Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France

<table class="figure-group"><tr class="fig-image" id="a"><td><object data="https://static.hindawi.com/articles/ah/volume-2019/4625787/figures/4625787.fig.002a.svgz" name="4625787.fig.002a" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(a) </b>Second-line treatment</td></tr><tr class="fig-image" id="b"><td><object data="https://static.hindawi.com/articles/ah/volume-2019/4625787/figures/4625787.fig.002b.svgz" name="4625787.fig.002b" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(b) </b>Third-line treatment</td></tr></table>

<div>Reasons for treatment discontinuation.</div>

Advances in Hematology

fig2

Figure 2

Figure 2: Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France 

Figure 2 | Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France 